Eplerenone and atrial fibrillation in mild systolic heart failure: results from the emphasis-HF (eplerenone in mild patients hospitalization and survival study in heart failure) study
JACC - Journal of the American College of Cardiology, 05/10/2012Swedberg K et al.
In patients with systolic heart failure and mild symptoms, eplerenone reduced the incidence of new onset atrial fibrillation or flutter (AFF). The effects of eplerenone on the reduction of major cardiovascular (CV) events were similar in patients with and without AFF at baseline.
Patients in New York Heart Association functional class II and with ejection fraction 35% were eligible for EMPHASIS–HF.
History of AFF at baseline was reported by investigators using the study case report form.
New onset AFF (in those with no history of AFF at baseline) was reported using a specific endpoint form; in a sensitivity analysis authors also examined the effect of eplerenone on AFF reported as an adverse event.
New onset AFF was significantly reduced by eplerenone: 25 of 911 (2.7%) versus 40 of 883 (4.5%) in the placebo group (hazard ratio [HR]: 0.58, 95% confidence interval [CI]: 0.35 to 0.96; p = 0.034).
The reduction in the primary endpoint with eplerenone was similar among patients with and without AFF at baseline (HR: 0.60, 95% CI: 0.46 to 0.79 vs. HR: 0.70, 95% CI: 0.57 to 0.85, respectively; p for interaction = 0.41).
The risk of cardiovascular (CV) death or hospital admission for worsening heart failure, the primary endpoint, was not significantly different in subjects with and without AFF at baseline (both study groups combined: HR: 1.23, 95% CI: 0.81 to 1.86; p = 0.33).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.